Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P50502 (Hip)
 7,003 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We assessed the agreement and repeatability of a software package for wear measurement in 19 total hip arthroplasties followed up for 4 to 8 years. Three observers with different levels of expertise (a hip surgeon [O1], a fellow [O2], and a medical student who is a research assistant of the laboratory in which the software was developed [O3]) determined the 2-dimensional wear and wear direction with the Hip Suite software (University of Chicago, Chicago, Ill). For intraobserver and interobserver comparisons, we used intraclass correlation coefficient (ICC) and repeatability. The intraobserver ICC for wear and wear direction was 0.83 and 0.78 for O1, 0.54 and 0.48 for O2, and 0.81 and 0.89 for 03. The interobserver ICCs were 0.43 (range, 0.07-0.87) for wear and 0.8 (range, 0.71-0.86) for wear direction. Computerized wear measurements have substantial intraobserver and interobserver variability, especially when performed by surgeons without extensive experience in the use of the software, a finding which questions its precision and validity.
 ...
PMID:The agreement and repeatability of computer-based wear measurement of total hip arthroplasties. 1816 41

Myalgias most commonly occur in polymyalgia rheumatica (PMR). About 45% of patients with giant cell arteritis present with symptoms of PMR. Other vasculitides may also lead to arthralgia and myalgia. While shoulder and pelvic pain is characteristic for PMR pain often also occurs in the back of the neck and in the region of the thoracic spine. In addition, patients often present with malaise, morning stiffness and weight loss. CRP and ESR are elevated. Ultrasound and MRI delineate minor synovitis, tenosynovitis and bursitis in the shoulder. Hip joint synovitis and trochanteric bursitis are also commonly seen. PMR should be distinguished from rheumatoid arthritis. The initial treatment comprises a prednisolone dose of 15-25 mg/day, followed by a weekly decrease of 1-2.5 mg. Once 10 mg/day has been reached the dose should be reduced more slowly.
 ...
PMID:[Myalgia in polymyalgia rheumatica, temporal arteritis and other vasculitides]. 1958 33